8-K: Encompass Health Q1 2026 Results and Guidance Increase

Encompass Health reported strong first-quarter 2026 growth and raised its full-year financial guidance.

Summary

• Net operating revenue grew 9.0% year-over-year to $1.586 billion.
• Adjusted EBITDA increased 11.2% to $348.8 million.
• Adjusted earnings per share rose 16.8% to $1.60.
• Total discharges increased 4.3% to 67,763.
• The company opened one new 49-bed hospital and added 44 beds to existing facilities.
• Full-year 2026 guidance was increased for revenue, Adjusted EBITDA, and adjusted earnings per share.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report characterized by solid growth, disciplined capital allocation, and increased full-year guidance.

Positives

• Revenue growth of 9.0% and Adjusted EBITDA growth of 11.2% demonstrate strong operational momentum.
• Adjusted earnings per share increased by 16.8% compared to Q1 2025.
• Full-year 2026 guidance was raised across all key metrics.
• Net leverage remains stable at 1.9x.
• Successful expansion of capacity with new hospital openings and bed additions.

Negatives

• Adjusted free cash flow declined 12.9% to $193.8 million compared to Q1 2025.
• Revenue reserves related to bad debt increased to 2.2% from 2.0% in the prior year period.
• Salaries and benefits expenses rose to $818.1 million from $762.3 million.

Risks

• Potential reductions or changes in Medicaid payment programs.
• Staffing shortages and competitive labor market pressures increasing costs.
• Regulatory changes, including CMS inpatient rehabilitation review choice demonstration (RCD) and TEAM initiatives.
• Increased Medicare audit activity and potential reimbursement denials.
• General economic conditions and inflation impacting construction and supply costs.

Future Outlook

The company raised its full-year 2026 guidance, now expecting net operating revenue of $6.375 to $6.470 billion, Adjusted EBITDA of $1.350 to $1.380 billion, and adjusted earnings per share of $5.89 to $6.11.

Management Comments

• We are very pleased with our start to 2026 as first quarter revenue increased 9.0% and Adjusted EBITDA grew 11.2%.
• Our value proposition and operating strategy continue to be validated and we remain highly optimistic about the long-term prospects of our business.

Industry Context

StockSavvy.ai notes that Encompass Health continues to solidify its position as the largest inpatient rehabilitation provider in the U.S., leveraging scale and a consistent de novo development strategy to outperform in a fragmented market.

Comparison to Industry Standards

• The company maintains a leading market share in the inpatient rehabilitation sector.
• Performance metrics, including discharge growth and EBITDA margins, remain consistent with top-tier healthcare facility operators.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from dividend payments and ongoing share repurchase authorizations.
• Creditors benefit from the extension of the credit agreement maturity.

Next Steps

• Host investor conference call on May 1, 2026.
• Continue execution of 2026 development pipeline, including opening 8 new hospitals.
• File March 2026 Form 10-Q.

Key Dates

Recommendation

The company demonstrates consistent growth, strong cash flow generation, and a clear strategy for capacity expansion, supported by an upward revision in full-year guidance.

Keywords

Encompass Health, EHC, inpatient rehabilitation, healthcare, earnings, Adjusted EBITDA, hospital expansion